IDO1 and myeloid sarcoma: These results together suggest that baseline IDO activity might be downregulated in stable MS, probably contributing to disease pathogenesis, whereas it is relatively upregulated during acute inflammatory relapse most probably reflecting an endogenous counter-regulatory reaction, which then responds to acute anti-inflammatory therapy (Figure 2).